Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 88

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 88
---
, our management will have significant flexibility in applying the net proceeds of this offering. In addition, while we have not entered into any outstanding binding agreements or
commitments relating to any significant transaction as of the date of this prospectus, we may use a portion of the net proceeds to pursue acquisitions, joint ventures, and other strategic transactions.

16

CAPITALIZATION The table below sets forth our cash and cash equivalents and capitalization as of March 31, 2025, the latest date for which we have unaudited interim financial statements and the information below available to us:

| • |     | on an actual basis; |

| • |     | on a pro forma basis to reflect the issuance and sale of $150,000,000 of ADSs in this offering at an assumed                                                                                                    
 offering price of $0.78 per ADS, the last reported sale price of our ADSs on the Nasdaq Global Market on June 9, 2025, after deducting the estimated commissions and estimated offering expenses payable by us. |

The pro forma information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual offering price, the actual number of ADSs offered by us and other terms of this offering determined at pricing. You should read this table in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus and “Use of Proceeds,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-Kfor the year ended December 31, 2024, as updated by our Quarterly Report on Form 10-Qfor the quarter ended March 31, 2025. The following information should be read in conjunction with the unaudited, condensed consolidated financial statements and related notes incorporated by reference in this prospectus. For more details on how you can obtain the documents incorporated by reference in this prospectus, see “Where You Can Find More Information; Incorporation of Information by Reference”.

|                                      |     | As of March 31, 2025 |          |   |     |           |          |   |
|:-------------------------------------|:----|:---------------------|---------:|:--|:----|:----------|---------:|:--|
|                                      |     | Actual               |          |   |     | Pro Forma |          |   |
| Cash and cash equivalents            |     | $                    |   47,709 |   |     |